1. Introduction {#sec1}
===============

The discovery of small non-coding RNAs, including microRNAs (miRNAs) and short interfering RNAs (siRNAs) ([@bib62], [@bib100], [@bib162], [@bib7]) has revolutionized our understanding of the regulation of gene expression. The effects of small RNAs on gene expression and control are generally inhibitory, and the corresponding regulatory mechanisms are therefore collectively subsumed under the heading of RNA silencing. The central theme throughout is that the small non-coding RNAs mainly serve as specific factors that combine effector proteins with target messenger RNAs (mRNAs) through complementary base pairing, and the core component of the effector machinery is a member of the argonaute protein superfamily. Compared with conventional small therapeutic molecules, miRNAs and siRNAs offer the advantages of being highly potent and able to act on "non-druggable" targets (for instance, proteins that lack an enzymatic function or that have a conformation that is inaccessible to traditional drug molecules) because they can be designed to affect virtually any gene of interest ([@bib37]).

The regulation of genes and genomes mediated by miRNAs and siRNAs can occur at the levels of chromosome segregation, chromatin structure, RNA processing, RNA stability, transcription or translation ([@bib24]). miRNAs, which are 20--25 nucleotides RNAs that regulate gene expression by targeting mRNAs at the post-transcriptional level, are purposefully expressed products of the genome originating from the organism itself ([@bib116], [@bib61]). miRNA gene transcription is executed by RNA polymerase II in the nucleus, leading to the formation of primary miRNA (pri-miRNA) with a double-stranded stem-loop structure. Then, the pri-miRNA is cleaved by a microprocessor complex (comprised of Drosha and the microprocessor complex subunit DCGR8) to form precursor miRNA (pre-miRNA, 10-100 nt). Subsequently, the pre-miRNA is transported by Exportin 5 from the nucleus to the cytoplasm. siRNAs, which are derived from the transposon, transgene trigger and virus or are transcribed from cellular genes, usually consist of 20--25 base pairs, and they regulate gene expression via a highly precise mechanism of sequence-directed gene silencing. After transporting to the cytoplasm, pre-miRNA and long double-stranded RNA (dsRNA) are processed by Dicer (known as a specialized ribonuclease (RNase) III-like enzyme) to form miRNA and siRNA, respectively. Then, both the passenger strand (sense strand) and the guide strand (antisense strand) of miRNA and siRNA are cleaved by the Argonaute 2 (AGO2) component, which belongs to RNA-induced silencing complexes (RISCs). Subsequently, the guide strand (antisense strand) of miRNA and siRNA remains associated with the RISC, whereas the passenger strand is detached from the active RISC. Finally, the guide strand of the miRNA guide the active RISC to its target mRNA with partial complementarity. The complementary pairing between mRNA and the mature miRNA typically occurs at the 3′ untranslated region (UTR) of the former and the seed region (nucleotides 2--7 from the 5′ end) of the latter, and other miRNA binding sites, such as the centred sites, 3' supplementary sites and bulged sites are considered to be atypical. In contrast, the siRNA must be fully complementary to its target mRNA ([@bib133], [@bib63]). Different combination modes between miRNA and siRNA with target mRNA produce different target gene silencing effects, which are closely related to common events (such as Dicer processing and RISC formation). The regulation of miRNA or siRNA degradation can occur at either the transcriptional or post-transcriptional level. Transcription is a major point of regulation in miRNA biogenesis, and it is always closely associated with the activity of polymerase II ([@bib91]). Drosha processing confers another important point of biogenesis for both miRNA and siRNA. For instance, a group of exoribonucleases called small RNA-degrading nuclease (SDN) proteins were reported to affect the stability of miRNA in plants ([@bib158]), however, which nucleases are responsible for miRNA degradation in animals remains unknown. There are two prominent questions closely related to the degradation of miRNA or siRNA, which are, how they are specifically marked for destruction and which ribonucleases catalyse the degradation reaction. The major difference between miRNAs and siRNAs is that the former have multiple mRNA targets, whereas the latter are highly specific with only one target. Since the discovery of siRNA, dsRNAs have been used as research tools to study the gene functions of various cell types. However, in mammalian cells, it has been verified that the delivery of long dsRNAs is closely related to the activation of the interferon (IFN) pathway, which is part of the defence mechanism against viral infection ([@bib54]). Because this effect can be either sequence-dependent or -independent, special care should be taken when designing siRNA therapeutics. The mechanism and pathway of miRNA and siRNA gene silencing are summarized in [Fig. 1](#fig1){ref-type="fig"} .Fig. 1Schematic gene silencing mechanism of miRNA and siRNA. miRNA gene transcription is executed by RNA polymerase II in the nucleus, leading to the formation of pri-miRNA, and then cleaved by Drosha to form pre-miRNA. Subsequently, the pre-miRNA is transported by Exportin 5 from the nucleus to the cytoplasm. siRNAs, which are exogenous products in origin, are derived directly from the transposon, transgene trigger or virus. After transporting to the cytoplasm, pre-miRNA and long dsRNA are both processed by Dicer to form miRNA and siRNA, separately. Then, both the sense strand of miRNA and siRNA are cleaved by AGO2, a component of RISC. The remaining anti-sense strand of miRNA and siRNA guide the active RISC to their target mRNA with partial complementarity and complementarity, respectively, leading to different target gene silencing effects. AGO2, Argonaute 2. RISC, RNA-induced silencing complexes.Fig. 1

Bone is a remarkable tissue playing key roles in critical functions in human physiology, consisting of fortification, movement and support of other vital organs, mineral storage, homeostasis and housing multiple progenitor cells, such as hematopoietic mesenchymal cells. Many cell subsets, including osteoblasts, osteoclasts and adipocytes, are involved in bone development, and the balance of bone formation, remodelling and reabsorption is extremely important to normal bone metabolism ([@bib21], [@bib55], [@bib56]). Osteoblasts are bone-forming cells derived from bone marrow stromal cells, and they produce dense, cross-linked collagen and specialized proteins. Osteoclasts are large, multinucleated, bone-resorbing cells that arise from a monocyte-macrophage lineage, and they secrete hydrogen ions to dissolve the mineral component of bone matrix and a lytic enzyme, cathepsin K, to digest the bone matrix (mainly type I collagen). Osteocytes are star-shaped cells that represent terminally differentiated osteoblasts, they are commonly found in mature bone, and they can permeate the mineralized bone matrix. Bone is remodelled continuously during adulthood through the resorption of old bone by osteoclasts and the subsequent formation of new bone by osteoblasts ([@bib130]).

A number of bone-related diseases, such as bone defects, osteoporosis, osteolysis, osteonecrosis, osteoarthritis and bone cancer, lead to a serious burden on the quality of life worldwide. Bone destruction begins to exceed bone formation after the age of 40 years old, leading to a local or systemic reduction of bone mass, which is well known as osteoporosis. For individuals with osteoporosis, bone fractures represent a life-threatening event, and the risk of fracture doubles for every 10% of bone that is lost ([@bib164]), while bone metastasis occurs in approximately 70% of patients with advanced prostate or breast cancer ([@bib184]). Bone metastases leading to excess bone loss are generally classified as osteolytic (bone destruction), and those leading to bone deposition are regarded as osteoblastic (bone formation). Both bone degradation and deposition have been verified to occur in the early metastatic process, and they are always incurable once tumours metastasize to bones ([@bib184]). Our increasing molecular understanding of disease-causing or disease-promoting genes of bone pathology has led to the discovery of numerous new molecular targets for the prevention and treatment of various of bone-related disorders. As a flourishing scientific field, the molecular mechanisms and therapeutic applications of the small non-coding RNAs (miRNAs and siRNAs) involved in bone-related diseases have been widely investigated in numerous studies. However, to date, no miRNA or siRNA targeting therapy-based clinical trials for musculoskeletal disorders have been initiated. This current review will focus on the roles of miRNAs in the regulation of bone formation and metabolism with an emphasis on the potential therapeutic strategies meidiated by miRNAs and siRNAs for the treatment of bone-related diseases.

2. Participation of miRNAs in bone formation {#sec2}
============================================

2.1. Osteogenesis-related miRNAs and target transcription factors {#sec2.1}
-----------------------------------------------------------------

Bone mesenchymal stem cells (BMSCs), originating from the bone marrow possess multiple differentiation potentials. They can differentiate into osteoblasts, adipocytes and chondrocytes ([@bib193]). Osteoblasts are the major cell types in bone development and tissue engineering ([@bib144]). Multiple transcription factors participate in osteogenic differentiation, and the production and mineralization of extracellular matrix (ECM) synthesized by osteoblasts are finely regulated by different miRNAs. Among them, *Runx2* and its downstream molecule *Osterix* are the most pivotal osteoblast-specific transcription factors that activate the relevant genes involved in the differentiation of preosteoblasts into mature osteoblasts and osteocytes, and the molecular mechanisms of the two bone -specific factors in the regulation of osteoblastogenesis were extensively described in our previous review ([@bib45]).

Many miRNAs are expressed during the osteogenic process induced in BMSCs, including cell proliferation, growth, matrix maturation and mineralization during the new bone formation ([Fig. 2](#fig2){ref-type="fig"} a). Several miRNA-profiling tools, such as high throughput sequencing of small RNA libraries, quantitative real time-polymerase chain reaction (RT-PCR) with locked nucleic acid primers, and microarray analysis, have been used to screen the osteogenesis-associated miRNAs ([@bib71], [@bib103], [@bib10]). Microarray analysis, which has been widely used for the investigation of genome-wide miRNA expression, can provide the fluctuating information about various miRNAs during osteogenic differentiation, while miRNA array profiling methods have been applied for the identification of miRNAs related to osteogenic differentiation in different cell lines. Although many miRNAs have been confirmed either to descend or to ascend during the osteogenic differentiation ([@bib103], [@bib10], [@bib76], [@bib102], [@bib44]), few of them, including hsa-miR-15b-5p, mmu-miR-29b-2-5p, hsa-miR-34a-3p, mmu-miR- 93-5p, hsa-miR-138-5p, hsa-miR-140-5p, mmu-miR-181a-5p, hsa-miR-196a-5p, mmu-miR-210-3p, hsa-miR-218-5p, mmu-miR-335-5p, hsa-miR-338-3p, hsa-miR-346, mmu-miR-433-3p, hsa-miR-2861 and mmu-miR-3960 ([@bib45]), are actually concerned with the gene expression related to skeletal formation. The biological, dynamic characteristics of several vital osteo-related miRNAs were discussed in our previous review ([@bib45]). To clarify the impact on the expression profiling of miRNAs during bone metabolism, Laxman et al. performed next-generation sequencing of miRNA derived from primary human osteoblast (HOB) cells treated with dexamethasone (DEX) and parathyroid hormone (PTH). They discovered that several miRNAs such as hsa-miR-205-5p, hsa-miR-203 and hsa-miR-30c-2-3p targeting runt-related transcription factor 2 (*Runx2)*, and hsa-miR- 320a targeting *β-catenin*, exhibited substantially different targeting gene-expression levels between DEX and PTH treatment ([@bib99]). Huang and colleagues reported that hsa-miR-320a negatively regulated the osteogenic differentiation of hBMSCs by repressing homeobox a10 (*HOXA10*) ([@bib75]). *HOXA10* is a bone morphogenetic protein 2 (BMP-2)-inducible gene, and it promotes osteogenic differentiation by activating *Runx2* and its target genes ([@bib65]). Additionally, mmu-miR-705 and mmu-miR-3077-5p were also observed to be negative regulators of osteoblast differentiation by targeting *HOXA10* ([@bib112]). Vishal et al. displayed that hsa-miR-590-5p enhanced osteoblast differentiation by indirectly stabilizing and protecting *Runx2* from Smad-specific E3 ubiquitin protein ligase 2 (*Smurf2*)-mediated degradation by targeting *Smad7*, which is antagonistic to osteoblast function ([@bib196]). Intriguingly, mechanical stimulation has been confirmed to trigger osteoblast differentiation via several mechanosignal transduction pathways, playing a momentous role in bone homeostasis ([@bib64], [@bib235], [@bib70], [@bib161]). Zuo et al. reported a mechanosensitive miRNA, hsa-miR-103a-3p, that exhibited negative effects on *Runx2* during cyclic mechanical stretch (CMS)-induced osteoblastogenesis, leading to decreased bone formation both *in vitro* and *in vivo* ([@bib251]). This innovative research has provided us with a feasible anabolic strategy for the treatment of skeletal disorders resulting from pathological mechanical loading with therapeutic inhibition of has-miR-103a-3p. It is well known that the skeleton is notably affected by the reduced differentiation capacity of stem cells with age ([@bib117]). Weilner and colleagues reported for the first time that the microRNA content of microvesicles from senescent cells contributes to an aged systemic environment for compromised osteoblastogenesis ([@bib216]). They indicated that endothelial hsa-miR-31-5p, which is secreted within senescent cell-derived microvesicles, is taken up by mesenchymal stem cells, in which it suppresses osteogenic differentiation by knocking down *Frizzled-3*. In addition, it has been pre-clinically and successfully tested in critical size defects models ([@bib39], [@bib40]), making hsa-miR-31-5p a very exciting target for bone tissue therapeutics in the near the future. Taken together, different miRNAs involved in bone formation exhibit diverse dynamic patterns, which could provide us with abundant information about the regulation of osteogenesis. However, various *in vitro* observations remain to be investigate further pre-clinically *in vivo*, and then some potential and promising candidates can be screened out after deliberative exploration.Fig. 2Schematic summary of miRNA role in osteoblast and osteoclast differentiation. (a) miRNAs regulating osteoblast differentiation, proliferation and function. A cohort of transcription factors tightly regulate osteoblast commitment, such as *Runx2*, *Osterix*, *ATF4* and *β-catenin*, from osteoprogenitors during skeletal development. (b) miRNAs effect various of molecules related to osteoclast commitment, such as RANKL and M-CSF, leading to changes in osteoclast activity *in vitro* as well as alterations in bone resorption *in vivo*. ATF4, activating transcription factor 4. HOXA10, homeobox a10. FZD3, Frizzled-3. LRP5, lipoprotein-receptor-related protein 5. M-CSF, macrophage colony-stimulating factor. *Runx2*, runt-related transcription factor 2. OPG, osteopontegrin. PTEN, phosphatase and tensin homologue. RANKL, receptor activator NF*κ*B ligand. STAT1, signal transducer and activator of transcription 1. SATB2, special AT-rich sequence-binding protein 2.Fig. 2

2.2. miRNAs control bone specific signalling pathways {#sec2.2}
-----------------------------------------------------

It has been proved that miRNAs target mRNAs through complementary base pairing to different sites in the 3'-untranslated regions, and they exert their biological functions through translational repression and/or being followed by deadenylation and degradation of their mRNA targets ([@bib11], [@bib41]). Multiple signalling pathways have been verified to participate in skeletal development and bone formation, and a good understanding of the diversity of these signals is of great importance to the manipulation of osteoblastogenesis mediated by miRNAs. A number of signalling pathways have been proved to govern the osteoblast-ogenic differentiation of BMSCs, including BMP/TGF-β and Wnt transduction, MAPK signalling, Notch signalling, IGF signalling, RANK-OPG-RANKL signalling, etc ([@bib45], [@bib243]).

Recently, Li et al. indicated that hsa-miR-23a-3p could impede the osteogenic differentiation of hBMSCs by targeting low-density lipoprotein-receptor-related protein 5 (LRP5) via inactivation of Wnt/β-catenin signalling ([@bib107]). LRP5 is a single-pass transmembrane protein, and absence of or variation of in LRP5 has been shown to result in decreased bone mass and osteoporosis ([@bib36], [@bib165]). Xiao\'s group demonstrated that hsa-miR-129-5p played a positive role in osteoblast differentiation by reducing signal transducer and activator of transcription 1 (*STAT1*) levels, leading to a dramatic increase in *Runx2* expression ([@bib224]). *STAT1* was originally regarded as a signalling molecule participating in immune regulation via the interferon pathway ([@bib136]), and several studies have also indicated that *STAT1* served as an important negative regulator of osteogenic differentiation by suppressing the expression of *Runx2* and *Osterix* both *in vitro* and *in vivo* ([@bib89], [@bib186]). Apart from targeting *Runx2*, hsa-miR-205-5p also negatively affects osteoblast differentiation by targeting special AT-rich sequence-binding protein 2 (*SATB2*) via the extracellular signal-regulated kinase (ERK) and p38 mitogen-activated protein kinase (MAPK) pathways ([@bib72]). In addition, Wei and colleagues indicated that mmu-miR-34b-5p and mmu-miR-34c-5p inhibited osteoblast proliferation by decreasing *Cyclin D1*, *CDK4* and *CDK6* accumulation while simultaneously suppressing osteoblast differentiation by decreasing *SATB2* accumulation during embryogenesis and postnatally ([@bib213]). However, this study could not confirm whether other putative targets, such as *Notch 1* or other genes, might additionally account for the capability of these two miRNAs to modulate osteoblastogenesis. Around the same time, Bae et al. verified that mmu-miR-34c-5p targeted multiple components of the Notch signalling pathway, including *Notch1/2* and *Jag 1*, to regulate osteoblastogenesis in bone homeostasis ([@bib9]). Considering the significant role of the Notch signalling pathway and abnormal osteoblastogenesis in osteosarcomas ([@bib43]), further investigations of the functional interaction between the miR-34 family and Notch signalling could potentially lead to efficient therapeutics in bone cancer.

2.3. miRNAs control bone remodelling factors {#sec2.3}
--------------------------------------------

The equilibrium of bone formation by osteoblasts and bone resorption by osteoclasts is subject to fine and tight regulation in normal bone metabolism ([@bib88], [@bib190]). Disruption of this balance, that is, decreased bone formation and/or excessive bone resorption, will lead to the development of osteoporosis ([@bib235], [@bib157]). The cross-talk between osteoblasts and osteoclasts is critical to the maintaining the equilibrium governed by osteoblast-directed osteoclastic bone resorption and osteoclast-directed osteoblastic bone formation ([@bib235], [@bib131]). As a monocyte-macrophage derived cell type, osteoclasts mainly locate near the bone formation surface ([@bib190], [@bib195]). The survival, proliferation, function and differentiation of osteoclasts are modulated by various cytokines and exogenous hormones ([@bib38]). It has been confirmed that receptor activator NF*κ*B ligand (RANKL) and macrophage colony-stimulating factor-1 (M-CSF), produced by activated T cells or osteoclasts, are two key cytokines involved in osteoclastogenesis ([@bib88], [@bib190], [@bib38]). Furthermore, immunoreceptor tyrosine-based activation motif (ITAM)-dependent costimulatory signals are also essential for osteoclastogenesis ([@bib93]), and many transcription factors, especially c-Fos and NF-*κ*B (p50 and p52), are fundamental to the normal differentiation of monocyte precursors into osteoclasts ([@bib58], [@bib77], [@bib49]).

miRNAs also control osteoclastogenesis by targeting relevant gene expression involved in this delicate process ([Fig. 2](#fig2){ref-type="fig"}b). Studies of the expression patterns of miRNAs revealed that 44 miRNAs were highly expressed during the maturation of osteoclast precursors ([@bib84]). The functions of hsa-miR-21-5p, miR-29 family, mmu-miR-31-5p, mmu-miR-124-3p, hsa-miR-133a-3p, mmu-miR-146a-5p, mmu-miR-223-3p, hsa-miR-503-5p, mmu-miR- 378-3p, hsa-miR-125a-5p, hsa-miR-148a-3p, hsa-miR-155-5p and hsa-miR-422a were systematically summarized in an excellent review ([@bib191]). It has been well documented that osteoblast-to-osteoclast communication occurs via direct cell-cell contact ([@bib78], [@bib143]). To understand whether other effective paracrine pathways exist in the interaction between the two cell types, Li and colleagues conducted miRNA-mediated osteoclast-directed osteoblastic bone formation in ovariectomized (OVX) mice, indicating that inhibition of osteoclast-derived exosomal mmu-miR-214-3p induced significantly suppressed osteoclastogenesis ([@bib108]). Additionally, mmu-miR-214-3p also negatively controlled osteogenic differentiation by targeting *Osterix* and activating transcription factor 4 (*ATF4*) ([@bib174], [@bib206]), promoting osteoclastogenesis via the PI3K/Akt pathway by targeting phosphatase and tensin homologue (*PTEN*) ([@bib244]). Based on the above research on miRNA-modulated osteoblastogenesis and osteoclastogenesis, miRNA-targeting therapeutics for metabolic bone disorders, such as osteoporosis, osteopenia and rheumatoid arthritis (RA)-related bone destruction, are anticipated approaches for clinical application.

3. miRNA-related bone disorders and potential targeting therapeutics {#sec3}
====================================================================

3.1. Osteoporosis {#sec3.1}
-----------------

Osteoporosis, resulting from an imbalance between osteoclastic bone resorption and osteoblastic bone formation, is characterized by tissue structural deterioration and low bone mineral density ([@bib192]). It has been reported that there are approximately 75 million people suffering from osteoporosis, and osteoporotic fracture is a common complication, leading to high healthcare expenditures and loss of productivity ([@bib140], [@bib170]). Glucocorticoids (GCs), as immunosuppressive and anti-inflammatory drugs, are extensively used to treat inflammation, autoimmune disorders and infection ([@bib185]). However, prolonged use of GCs has been closely associated with osteoporosis, and GC-induced osteoporosis (GCOP) is the second most common aetiology of all types of osteoporosis ([@bib94], [@bib218]). The suppression of osteoblast activity, differentiation, maturation and lifespan are regarded as the major mechanisms involved in GC-induced inhibition of bone formation ([@bib217], [@bib167]). Moreover, capacious marrow adipogenesis is observed in glucocorticoid-mediated bone deterioration as well ([@bib189]). As the most common degenerative bone disease in elderly women, postmenopausal osteoporosis is caused by a remodelling imbalance between bone formation and bone resorption due to oestrogen deficiency. ([@bib68], [@bib166]) Shi and colleagues discovered that mmu-miR-17-5p and −20a-5p suppressed GC-induced osteoclast differentiation and targeted RANKL in osteoblast cells ([@bib175]). This is the first report regarding microRNA-targeting RANKL in osteoclastogenesis, however, they did not explore how dexamethasone (Dex) regulated mmu-miR-17/20a-5p expression in osteoblast, which remains to be further investigated. Wang et al. observed that mmu-miR-29a-3p protected rats from GC-induced bone loss and fragility by regulating *Wnt* and its inhibitor Dkk-1, making miR-29a-3p a potential candidate for alleviating GCOP ([@bib207]). The inhibition of histone deacetylase (HDAC) 4 with miR-29a-3p restored the acetylation state of *β-catenin* and *Runx2*, ameliorating the harmful effects of glucocorticoids on osteoblastic mineralization ([@bib92]). However, the long term effect of exogenous miR-29a-3p signaling on immune response, tissue integrity, or animal physiology warrants further evaluation.

Various of investigations on the role microRNAs in *in vivo* human circulating monocytes in the etiology of osteoporosis have been extensively established in order to figure out potential biomarkers or targeting therapeutics. Wang et al. illustrated that hsa-miR-133a-3p negatively regulated three potential osteoclast-related genes, chemokine (C-X-C motif) ligand 11 (*CXCL-11*), chemokine (C-X-C motif) receptor 3 (*CXCR-3*) and solute carrier family 39 A1 (*SLC-39A1*), indicating that hsa-miR-133a-3p in circulating monocytes might serve as a potential biomarker for postmenopausal osteoporosis ([@bib204]). In addition, hsa-miR-442a could down-regulate certain gene expression levels related to osteoclastogenesis inhibition, including cluster of differentiation 226 (*CD226*), phosphoprotein associated with glycosphingo-lipid microdomains 1 (*PAG-1*), insulin-like growth factor 1 (*IGF-1*) and transducer of ERBB2 (*TOB-2*), making hsa-miR-442a another possible biomarker underlying post-menopausal osteoporosis ([@bib18]). Furthermore, hsa-miR-194-5p was identified as a potential biomarker of postmenopausal osteoporosis according to Meng et al.'s microarray analysis ([@bib135]). Meanwhile, You et al. observed that hsa-miR-27a-3p-targeting myocyte enhancer factor 2c (*Mef2c*) was markedly decreased in osteoporotic patients through microarray analysis, and it was necessary for the shift of BMSCs from osteogenic into adipogenic differentiation during the development of osteoporosis ([@bib233]). Overexpression of hsa-miR-133 was shown to induce postmenopausal osteoporosis by impeding osteogenic differentiation of hMSCs through the down-regulation of *SLC39A1*, which is positively correlated with *Runx2* and *Osterix* ([@bib123]). Weilner and colleagues performed an explorative analysis of numerous miRNAs in serum samples obtained from patients with recent osteoporotic fractures, and they discovered that hsa-miR-10a-5p, hsa-miR-10b-5p, hsa-miR-22-3p were significantly up-regulated, whereas hsa-miR-133b, hsa-miR-328-3p and hsa-let-7g-5p were down-regulated, and they also demonstrated regulatory effects on the osteogenic differentiation of BMSCs *in vitro* ([@bib215]). Moreover, this team also investigated the expression levels of circulating miRNAs in patients with diabetic bone disease and postmenopausal osteoporosis. They identified hsa-miR-550a-5p and hsa-miR-382-3p as the most promising circulating miRNAs for diabetic bone diseases, and hsa-miR-382-3p and hsa-miR-188-3p as the most promising circulating miRNAs for postmenopausal osteoporosis ([@bib67]). Identifying and evaluating patients at relatively high risk for osteoporosis-associated fragility fracture are of great significance to disease prevention and management, and further in-depth exploration of these differentially expressed miRNAs in bone tissue and in larger validation cohorts should be well established to confirm whether miRNAs can serve as potential pharmaceutically biomarkers and clinically applicable therapeutic targets for osteoporosis.

Down-regulation of mmu-miR-34a-5p-targeting cell cycle factors (*CDK4*, *CDK6* and *Cyclin D1*) led to impaired BMSC osteogenic differentiation and aggravated osteoporosis in dexamethasone-induced rodent models through the Notch signalling pathway. Therefore, mmu-miR-34a-5p might be a conceivable therapeutic target for GCOP ([@bib85]). Li et al. reported that mmu-miR-140-3p and mmu-miR-214-3p impeded sponges via constructed Cre/loxP-based hybrid baculovirus vectors, demonstrating improved bone formation and mitigated excessive bone resorption in an osteoporotic bone defect rat model, thus paving a new avenue to the treatment of osteoporotic bone defects through combination of osteogenic factors and functional miRNAs ([@bib109]). In addition, Krzeszinski and colleagues found that mmu-miR-34a-5p knockout and heterozygous mice exhibited elevated bone resorption and reduced bone mass by targeting transforming growth factor-β-induced factor 2 (*Tgif2*), indicating that miR-34a-5p was a critical osteoclast suppressor and a potential therapeutic strategy to combat osteoporosis, and could exert both anti-catabolic and anabolic effects compared to current drugs that are solely anti-catabolic ([@bib95]). This innovative study paves the way for future epidemiological and clinical studies to investigate the pathological and therapeutic roles of the miR-34a-5p-*Tgif2* pathway in human. It has been well established that oxidative stress plays a critical role in the development of postmenopausal osteoporosis, which is attributed largely to the decline of the enzymatic antioxidant system ([@bib128]). Liao et al. illustrated that the expression of mmu-miR-705 was significantly enhanced in ovariectomized (OVX) mice through the TNF-α activated NFκB pathway, leading to the suppression of forkhead box O1 (FoxO1) protein, which is essential for defending against oxidative damage caused by oestrogen deficiency during osteoporosis ([@bib114]). This study indicated that NFκB pathway is a major target for the treatment of osteoporosis, however, global inhibition of NFκB pathway may be not an ideal strategy in clinic because NFκB signaling is of great importance for immnue system and other physiological. Thus, modulation of its downstream signalling will be a promising strategy. In addition, this group also reported that mmu-miR-705 and mmu-miR-3077-5p could mediate the shift of BMSC cell lineages into adipocytes in osteoporosis by targeting *HOXA10* and *Runx2*, respectively ([@bib113]). Furthermore, TNF-α was reported to impede bone formation by down-regulating the expression of hsa-miR-21-5p in oestrogen deficiency-induced osteoporosis, with enhanced expression of *Spry1* ([@bib230]), which negatively regulates the FGF and ERK-MAPK signalling pathways.

3.2. Bone defects {#sec3.2}
-----------------

The aetiologies of bone defects mainly include osteoporosis, trauma and bone tumour resection. Minor bone defects can be self-rehabilitated; however, bone restoration can be difficult in cases of critically sized bone defects. Traditionally, grafting (including autografts, allografts and xenografts) and the introduction of metal implants were the gold standard treatment for these defects. Nevertheless, several common complications, such as tissue function loss, implant-related infection and implant rejection, have restricted the therapeutic effects of these methods. More recently, bone tissue engineering, which provides a relatively disease-free implant for damaged bones without imposing any obvious adverse effects on the skeleton and its environment, has emerged as an alternative strategy to resolve these problems originating from traditional therapy for bone defects. Bioactive and biogradable scaffolds with a similar micro-architecture to that of bone tissues, which can be fabricated by various methods such as electrospinning ([@bib134]), freeze drying ([@bib31]), low-temperature rapid prototyping ([@bib155]), 3D printing ([@bib245]), etc., have been widely used to accelerate and enhance bone repair for critically sized bone defects. Biomaterial-mediated miRNA delivery for bone regeneration is being extensively exploited based on the molecular mechanisms discussed above. The miRNA expression profiles of BMSCs at the defect site can be differentially altered by osteoinductive and osteoconductive biomaterials. Thus, genetically modified scaffolds incorporating with various miRNAs could pave the way for new manipulation of osteoblastogenesis and osteoclastogenesis during bone restoration.

Palmieri et al. first effort to investigated the regulation of miRNAs in osteoblast-like cells via calcium sulphate (CaS) by using microarray techniques, providing a better understanding of the molecular mechanism of interactions between biomaterials and bone regeneration ([@bib150]). The nano-structure interface of biomaterials was shown to promote bone mineralization through the regulation of relevant miRNA expression. Mahmood et al. observed that many osteogenic genes were differentially regulated by silver nano-particles (AgNPs) ([@bib125]). Apart from investigating the effects of different biomaterials on whole miRNAs profiles, numerous miRNA-targeting strategies with varied biomaterials to treat bone defects have been thoroughly studied. Anti-miRNA oligonucleotides (AMOs), which are complementary to target miRNAs, were used to suppress the expression of certain critical miRNAs in osteoblast differentiation. Yan et al. reported BMSC sheets incorporating with non-viral oligonucleotide anti-mmu-miR-138-5p by a vitamin C-induced method, which displayed significantly improved bone regeneration *in vivo* by activating the ERK1/2 pathway via targeting *Runx2* ([@bib229]). It was verified that the miR-29 family could negatively regulate the extracellular matrix (ECM) production during the early stage of osteogenesis ([@bib87]), and inhibition of the miR-29 family could promote ECM synthesis in osteoblastogenesis. James et al. determined that mmu-miR- 29a-3p inhibitor-loaded gelatine nanofibre scaffolds prepared by electrospinning could increase ECM deposition, which might serve as a novel platform for exploiting miRNA-based therapeutics in bone defects ([@bib80]). It was identified that miR-133a served as a direct negative regulator of the master transcription factor of osteogenesis, *Runx2* ([@bib45]). Castaño and colleagues fabricated porous collagen/nano-hydroxyapatite scaffolds with miR-133a-inhibiting complexes, demonstrating significantly promoted osteogenic differentiation *in vitro*, thus offering potential applications for bone repair and tissue engineering ([@bib25]). However, complete inhibition of such functional miRNAs may trigger unwanted side-effects, thus, systematic investigations of the stability of the delivery system and *in vivo* validation remain to be performed to verify the therapeutic efficacy of such an antago-miRNAs-based osteoconductive scaffolds for bone engineering.

In addition, the osteogenesis of BMSC sheets was greatly ameliorated by hsa-miR-21-5p-loaded chitosan/hyaluronic acid nanoparticles ([@bib211]). Therefore, such miRNA-based cell sheet engineering might serve as a novel approach to more rapid and robust bone regeneration clinically. Deng and colleagues reported poly(glycerol sebacate) (PGS) scaffolds loaded with anti-miR-31-expressing BMSCs, showing better biocompatibility and bone regeneration when repairing critical-sized calvarial defects (CSDs) in rats ([@bib40]). They also systematically evaluated the roles of mmu-miR-31-5p-modified adipose tissue-originated stem cells (ASCs) both *in vitro* and *in vivo*, indicating that knockdown of miR-31-5p by lentivirus (antisense) in ASCs exhibited dramatically improved repair of CSDs by targeting *Runx2* and *SATB2* ([@bib39]). Silver nanoparticle (SNP) compounds conjugated with hsa-miR-148b-3p, a positive regulator of osteogenesis ([@bib168]), enhanced osteogenic differentiation by improving ALP activity and calcium mineralization ([@bib156]). Thus, this study provided the possibility of 3D scaffolds combined with miR-148b-3p-SNP conjugates as a light activated miRNA delivery vehicle and the capability to modulate the osteogenic differentiation using light as a non-invasive triggering modality. Moreover, the incorporation of mmu-miR-26a-5p-transfected ASCs into porous hydroxyapatite scaffolds also showed satisfactory bone repair in a rat tibial defect model ([@bib208]). The osseointegration between titanium implants and surrounding bone tissues is of great importance to the immobilization of large bone defects. To improve the loading capability of titanium-based implants, the microarc-oxidation method was introduced to form micropore structures. For instance, hsa-miR-21-5p-loaded chitosan/hyaluronic acid nanoparticles coated over the surface of titanium using cross-linking methods could promote the osteogenic differentiation of hBMSCs ([@bib209]), providing a unique cross-linking-mediated therapeutic approach to prepare miRNA-loaded metal implant surfaces for bone repair.

3.3. Primary bone tumor and secondary metastasis {#sec3.3}
------------------------------------------------

miRNA expression was first linked to cancer in 2002, initially with chronic lymphocytic leukaemia and then with other different types of malignancies ([@bib137]). It has been generally recognized that some miRNAs function as tumour-inhibitor genes, whereas others alternatively behave as oncogenes ([@bib146]). The development of cancer can be attributed to the dysregulation of miRNA expression to a certain extent, making miRNA-targeted interventions a promising approach for the diagnosis, as well as the treatment, of different malignancies. Primary bone tumours encompass a broad range of types, including osteosarcoma (OS), Ewing sarcoma (ES), chondrosarcoma (CS), multiple osteochondromatosis (MOC), and giant cell tumour of bone (GCTB), etc., among which osteosarcoma and Ewing sarcoma are the two most common malignant primary tumours of bone ([@bib147]).

The roles and target genes of miRNAs in primary bone tumours and metastatic bone tumours were elucidated in an elaborative review ([@bib146]). Currently, there appear to be a few new miRNAs and concomitant targets associated with bone neoplasms. Sun and colleagues observed that hsa-miR-646 was a suppressor of OS cell metastasis by down-regulating fibroblast growth factor 2 (*FGF-2*) ([@bib181]). Shi et al. found that the proliferation, migration, invasion and epithelial-mesenchymal transition (EMT) of OS cells were effectively prevented by overexpression of hsa-miR-204-5p directly targeting Sirtuin 1 (*Sirt 1*) ([@bib176]). *Sirt 1* is a type of class III histone deacetylase that promotes tumourigenesis and metastasis ([@bib115]). Moreover, *Sirt 1* is also a direct target of hsa-miR-126-5p that suppresses the proliferation of OS cells by down-regulating *Sirt 1* expression ([@bib227]). Wu et al. reported that the expression of hsa-miR-409-3p in OS tissue was significantly lower than in adjacent non-tumour tissue, and it inhibited OS cell migration and invasion by targeting catenin-δ1, which is encoded by *CTNND1* and serves as a tumour-suppressing or oncogenic factor, depending on the cancer type ([@bib222]). This study for the first time discovered a unique function of catenin-δ1 in osteosarcoma progression, and further studies by exploring the interconnected pathway in relevant models will be beneficial to fully elucidate the function of miR-409-3p/catenin-δ1 in osteosarcoma development. Zhou et al. observed that hsa-miR-20a-5p exerted oncogenic effects on OS cells via direct inhibition of early growth response 2 (EGR-2) ([@bib249]), which negatively regulates cell proliferation and cell cycle ([@bib194]), indicating that miR-20a-5p may serve as a promising prognostic and therapeutic target for OS. He and colleagues discovered that up-regulation of hsa-miR-106a-5p could inhibit OS proliferation, migration and invasion by targeting high-mobility group AT-hook 2 (*HMGA2*) ([@bib66]), which is critical to the chromosomal aberrations and tumourigenesis ([@bib53]).

The 5-year survival was reported at approximately 20% in osteosarcoma patients with lung metastasis ([@bib177]), and this relatively poor survival might be caused by the difficulty of eliminating cancer stem cells (CSCs), a small subset of tumour cells and also the possible primary cause of tumour metastasis and relapse ([@bib138]). hsa-miR-26a-5p was shown to play a positive role in osteoblastogenesis, and it could suppress the CSC phenotype and tumour growth of OS by inhibiting Jagged1/Notch pathway, which plays a pivot role in maintaining CSCs function ([@bib121]). Thus, the metastasis of OS might be effectively prevented using certain miRNAs to suppress CSC function. The reprogramming of metabolic pathways, such as increased *de novo* lipid synthesis, represents one of the most critical and common features of cancer cells. As the precursor of *de novo* lipogenesis, ATP citrate lyase (ACLY) is a cross-link between the mevalonate pathways and fatty acid synthesis, and it is one of the most significant components of ACLY metabolic post-transcriptional regulation ([@bib236]). The tumour growth and metastasis of OS could be inhibited by hsa-miR-22-3p targeting ACLY, yielding an effective therapeutic approach to different cancers ([@bib226]). Apart from inhibition of the Notch-1 pathway ([@bib104]), hsa-miR-145-5p also acted as a tumour inhibitor of OS via direct suppression of friend leukaemia virus integration 1 (*FLI-1*) that enhances oncogenesis ([@bib223]). This is the first observation of miR-145-5p/*FLI-1* interaction in OS cells, and the direct interaction between this miRNA and proliferation of OS cells remains to be further investigated.

Extensive bone resorption is one of the most featured characteristics of GTCB, causing regional pain and high risk of pathological fractures ([@bib35]). RANK-expressing monocytic cells are regarded as the neoplastic component of GTCB ([@bib8]), thus, RANKL-targeted intervention by miRNAs could be a meaningful method to restrain the development of GTCB. As a member of the miR-106b-25 cluster, hsa-miR-106b-5p was verified to be a novel inhibitor of osteoclastogenesis and osteolysis by targeting RANKL and other cytokines (IL-8, MMP2 and TWIST) in GTCB ([@bib210]), while hsa-miR-126- 5p also restrained osteoclast differentiation and bone resorption in GTCB through inhibition of matrix metalloproteinase-13 (MMP-13) and parathyroid hormone-related protein (PTHrP) ([@bib220], [@bib248]). Meanwhile, the osteoclast differentiation and bone resorption in GCTB involve various factors, therefore, miR-126-5p might influence some other factors expression in the process via either a direct or indirect way, which requires further study in the near future. Some hypoxia-induced factors, such as vascular endothelial growth factor (VEGF) and hypoxia-inducible factor 1α (HIF-1α), were overexpressed in sacral GCTB samples, and they are closely related to tumour microvessel density ([@bib50]). Guo et al. elucidated for the first time that hsa-miR-210-5p was up-regulated by HIF-1α in GCTB stromal cells, suggesting an effective strategy to suppress the hypoxic adaptation of GCTBs ([@bib60]).

The most common metastatic bone tumours are the carcinomas derived from the prostate, breast and lung. Ma et al. first proposed the involvement of miRNAs in metastasis in 2007, indicating that hsa-miR-10b-5p initiated the invasion and metastasis of breast cancer ([@bib124]). This significant study opened the door for the investigations of the role of miRNAs in mediating cancer metastasis. Bone metastasis is one of the most typical characteristics of prostate cancer (PC) clinically, and it is usually treated with androgen deprivation therapy to relieve symptoms and restrain tumour growth. Comprehending the molecular mechanisms of the miRNAs that regulate metastasis is essential to improve the therapeutic outcomes of patients ([@bib171]). Liu et al. reported that low levels of androgen-regulated hsa-mir-1-2 could promote PC bone metastasis by activating SRC through the ERK signalling pathway, suggesting that SRC activity might be regarded as a potential biomarker in patients receiving androgen deprivation treatment ([@bib119]). Aberrant activation of Ras and Wnt signallings were critical events during the development of PC bone metastasis ([@bib23], [@bib96]). hsa-miR-34a-5p was reported to restrain the bone metastasis of Ras-activated PC via the Wnt signalling pathway by targeting transcription factor 7 (*TCF7*). *TCF7* plays a vital role in enhancing the oncogenic activity of the Wnt signalling pathway, and the up-regulation of *TCF7* depends on the suppression of miR-34a ([@bib28]). It has been well established that transforming growth factor-β (TGF-β) signalling promotes malignancy in tumourigenic tumour cells while impeding tumour growth in benign/normal tissues ([@bib6]). TGF-β serves as a momentous factor in facilitating bone metastasis by activating mammalian target of rapamycin (mTOR) function. mmu-mir-96 was observed to be up-regulated by TGF-β through Smad-dependent transcription in the progression of PC bone metastasis, and *AKT1S1*, the translated protein of which negatively regulates mTOR kinase, was identified as a downstream target of the TGF-β-miR-96 pathway ([@bib178]). Endothelial nitric oxide synthase (eNOS) has been detected in clinical PC tissues and is positively correlated with the invasion, metastasis and antiandrogen resistance of PC ([@bib142], [@bib234]). Fu and colleagues found that hsa-miR-335-5p and hsa-miR-543 restrained bone metastasis in PC by targeting eNOS, indicating that these two miRNAs might be used clinically for the prediction of bone metastasis in PC patients ([@bib51]). Even though the regulatory role of miRNAs in the control of metastatic bone tumors has been well described in numerous investigations, the specific network and interaction remains to be further explored in the future.

3.4. Osteoarthritis {#sec3.4}
-------------------

Osteoarthritis (OA) is the most prevalent degenerative bone joint disease characterized by progressive deterioration of articular cartilage, sclerosis of subchondral bone and synovial hyperplasia ([@bib129]). Over the past decades, there has been an increasing concern about the functional and therapeutic roles of miRNAs in OA, and some elegant reviews have systematically elucidated miRNA-mediated homeostasis and pathogenesis in OA ([@bib139], [@bib221], [@bib179]). Here, we only focus on several of the most recently reported miRNAs involved in the pathogenesis and targeting therapeutics of OA. Hu et al. reported that hsa-miR-139-5p promoted the inhibition of chondrocyte proliferation and migration in human chondrocyte CHON-001 cells by suppressing insulin-like growth factor 1 receptor (*IGF1R*) and eukaryotic translation initiation factor 4 gamma 2 (*EIF4G2*) ([@bib73]), both of which play pivotal roles in facilitating the translation initiation and proliferation of cancer cells ([@bib33], [@bib126]). Kang et al. observed that hsa-miR-23a-3p expression was significantly higher in OA cartilage than in normal tissues and it decreased chondrocyte ECM synthesis by targeting *Smad3*, a regulator of TGF-β in the homeostasis and restoration of cartilage ([@bib86]). In addition, *Smad3* was also a target of hsa-miR-16-5p, which might contribute to the deterioration of OA ([@bib106]). As a proinflammatory cytokine, IL-1β is an inhibitor of chondrocytes proliferation and collagen biosynthesis ([@bib57]). IL-1β-mediated overexpression of inducible nitric oxide synthase (iNOS) strongly contributes to cartilage deterioration and inflammation ([@bib1]). Rasheed and colleagues indicated that up-regulation of hsa-miR-26a-5p in human OA chondrocytes could effectively restrain the expression of iNOS via activation of the NF-κB pathway ([@bib160]). In addition, IL-1β inhibited the expression of miR-30a by recruitment of activator protein 1 (AP-1) and overexpression of disintegrin-like and metalloproteinase with thrombospondin-5 (ADAMTS-5), leading to aggravated degradation of cartilage matrix in OA ([@bib81]). Similarly, hsa-miR-142-3p and mmu-miR-210-5p could suppress inflammation and chondrocyte apoptosis in OA via the NF-κB pathway by targeting *HMGB-1* and death receptor 6 (*DR6*), respectively ([@bib212], [@bib240]). Inhibited production of proteoglycans and an imbalance between collagens I and II induced by fibroblast growth factor 2 (FGF2) are among the important pathogenic factors in OA ([@bib42]). FGF2-induced ADAMTS expression inhibited the transcription of hsa-miR-105-5p by targeting *Runx2*, thus accelerating the progression of OA ([@bib82]). In addition to the inflammatory factor-mediated cartilage deterioration, mechanical stress is also a significant biochemical factor involved in the initiation and progression of OA, especially traumatic OA. Yang et al. reported that mechanically responsive miR-365 was significantly increased after cyclic loading and IL-1β stimulation by targeting histone deacetylase 4 (HDAC4), which acts as a potent suppressor of chondrocyte hypertrophy. Thus, inhibition of hsa-miR-365a-3p might be an effective therapy for the prevention and treatment of traumatic OA ([@bib231]). In short, inflammation-mediated degeneration and apoptosis of cartilage are the most important causes of the progression of OA, and regulation of the miRNAs involved in the pathophysiological process in OA could pave new and anticipated therapeutic avenues to treat this degenerative and inflammatory disorder.

4. Potential targeting therapeutics of siRNAs in bone disorders {#sec4}
===============================================================

4.1. siRNA-mediated bone formation and resorption {#sec4.1}
-------------------------------------------------

Silencing of gene expression in a sequence-specific manner at post-transcriptional levels can be achieved by small-interfering RNAs (siRNAs), which were initially proposed by Fire and colleagues in 1998 and were developed rapidly to treat musculoskeletal disorders over the last two decades ([@bib47]). The discovery of this process has opened the doors to the development of siRNA-based therapeutics. Recently, siRNAs have been fully exploited to regulate the expression of various proteins involved in many therapeutic conditions, such as osteoporosis, osteoarthritis, and bone regeneration, etc. However, siRNA-based therapy is still gaining ground in musculoskeletal tissue repair, bone regeneration and tumour suppression. With advancement in the understanding of the targeting biological pathways involved in bone regeneration and also the rapid progress in siRNA technologies, application of siRNAs for bone-related disorders has great therapeutic potential. siRNA therapeutics targeting the osteoclast-mediated bone resorption involved in osteoporosis and osteoarthritis have been well elucidated in a few excellent reviews ([@bib173], [@bib198], [@bib199]). In this review, we mainly focus on siRNA-mediated bone regeneration and several newly released investigations of the treatment of bone resorption using siRNA-targeting technologies.

Two major categories of DDSs used for siRNA delivery in therapeutic applications for bone regeneration are lipid-based and polymer-based systems. Currently, the majority of commercial transfection reagents are modified cationic liposome-based systems. Farnesyl pyrophosphate synthase (FPPS), an enzyme in the mevalonate pathway, is the inhibition target of alendronate, which is a potent FDA-approved nitrogen-containing bisphosphonate drug. Knockdown of FPPS activity mediated by siRNA exhibited selectively inhibited osteoclast-mediated bone resorption and promoted bone mass maintenance without negative effects on the proliferation of preosteoblasts ([@bib203]). This is the first report to knock down the molecular target of clinically common nitrogen-containing bisphosphonates through siRNA. However, the direct effect of FPPS changes on preosteoblasts mineralization is still unclear, and further investigation is required to confirm whether down-regulation of FPPS via siRNA influence the osteoblast-osteoclast communication. Ríos and colleagues administered siRNA silencing prolyl hydroxylase domain-containing protein 2 (siPHD2) and guanine nucleotide-binding protein alpha-stimulating activity polypeptide 1 (siGNAS1) via Ambion (A commercially purchased polyamine-based transfection agent), inducing enhanced osteogenesis *in vitro* and bone formation *in vivo* ([@bib163]). Nevertheless, the complex and different intercellular mechanisms of siPHD2 and siGNAS1 during the regulation of bone formation remains to be further determined, and the prefabricated bone defect model with no mechanical loading could impair the clinical application potential of this siRNA-based targeting therapeutic. Jia et al. fabricated a siRNAs-incorporating chitosan sponge, within which two types of siRNA-Lipofectamine 2000 complexes targeting soluble vascular endothelial growth factor receptor 1 (siFlt-1) and casein kinase 2 interaction protein 1 (Ckip-1) were delivered together. This composite siRNAs-delivered scaffold showed satisfactory angiogenesis and osteogenesis in BMSCs and bone repair efficacy *in vivo* ([@bib83]). Furthermore, Guo and colleagues also reported a similar Ckip-1-siRNA-Lipofectamine 2000 complex, demonstrating increased osteogenic differentiation *in vitro* and reversal of bone loss in osteoporotic mice ([@bib59]). Zhang and colleagues developed a bone-formation surface-targeting system based on dioleoyl trimethylammonium propane (DOTAP) cationic liposomes, which displayed high affinity for poorly crystallized hydroxyapatite (HA) due to an (AspSerSer)~6~ moiety. An osteogenic siRNA targeting casein kinase-2 interacting protein-1 (Plekho1) was encompassed into the liposomes, producing significantly increased bone micro-architecture and bone formation in both healthy and osteoporotic rats ([@bib237]). Subsequently, Liang et al. encapsulated the same siRNA into a more efficient osteoblast-specific aptamer-functionalized lipid nanoparticle (LNPs-siRNA) to promote the selective uptake of Plekho1 siRNA, which might act as a novel and desirable siRNA-based bone anabolic strategy to improve bone mass in osteoporosis ([@bib110]). Bone-specific targeting delivery system as discussed above is a promising approach to specially delivering siRNA drugs to bone-formation surfaces and the osteogenic cells that reside there, thus, providing a potential solution to the bottleneck in clinical translation of siRNA-based bone anabolic therapeutics in the near future. Moreover, lipidoids, which possess a similar chemical structure to liposomes, are another new type of lipid-based nanoparticle. Lipidoids gained significantly higher transfection efficiency over Lipofectamine 2000 in human umbilical vein endothelial cells (HUVECs) at a low serum level (2%) ([@bib52]). Ramasubramanian et al. performed delivery of BMP-2 DNA along with Noggin and guanine nucleotide binding protein alpha-stimulating activity polypeptide (*GNAS*) targeting siRNA in an immortalized human foetal osteoblast cell line (hFOB1.19) using a lipidoid called NA114, which was previously reported to be an efficient siRNA carrier ([@bib30]). This study determined that this osteoinductive genes delivery caused decreased cell viability and promoted cell apoptosis in a dose-dependent manner, emphasizing the significance of distinguishing the biological effects of osteoinductive signals on various cell types in bone regeneration ([@bib159]). Targeting the component of the triad OPG/RANKL/RANK by siRNA technique seems to be a promising approach to regulate the osteoclastogenesis. Córdova and colleagues reported local administration of a RANK-targeting siRNA, delivered by the cationic liposome DMAPAP/DOPE, which revealed effectively impeded osteolysis and increased bone formation in a polyethylene (PE) particle-induced osteolysis model in mice ([@bib34]). This study demonstrated for the first time an effective inhibition of particle-induced osteolysis *in vivo* using a RANK-directed siRNA-sequence. Interestingly, the unexpected bone formation observed in siRNA-treated mice indicated that the injection of this cationic liposome might produce a favourable local anabolic microenvironment, and further study remains to be established to understand the biological effects of delivery system on the targeting cells or tissues, which may be useful to improve the biocompatibility of the siRNA delivery system.

As other siRNA DDSs, synthetic and natural polymers have been widely studied and modified to improve intracellular uptake, and they were elaborately analysed in a previous review ([@bib219]). Wang and colleagues reported a local siRNA delivery strategy to target selectively and to suppress osteoclastogenesis at bone sites with osteoporosis. They fabricated passive phagocyte-targeting poly(lactic-*co*-glycolic acid) (PLGA) microparticles and incorporated them within biomedical grade calcium-based injectable bone cement to deliver RANK siRNAs to both osteoclasts and their precursors, providing a proof of concept to use a locally delivered siRNA therapeutic strategy for direct targeting of osteoporosis sites ([@bib205]). We have discussed the role of glucocorticoids (GCs) in osteoblastogenesis and osteoclastogenesis in this review; therefore, designing siRNA targeting GC receptor (GCR) could be a feasible approach for regulating the function of hBMSCs, which was explored in an *in vitro* study ([@bib214]). Moreover, Hong et al. reported that GCR-siRNA-delivered PLGA microparticles showed effectively inhibited, detrimental effects of endogenous GC on hBMSCs, with improved osteogenic proliferation and differentiation ([@bib69]). Wang et al. fabricated a site-specific bone-targeting system based on an octa-aspartic acid sequence (Asp8) and bisphosphonates, which was demonstrated to favorable recognize and strongly bind to biomineral (e.g. hydroxyapatite) surfaces ([@bib200]). In their studies, a highly hydrophilic synthetic polymer, N-(2-hydroxypropyl) methacryl-amide (HPMA), was coupled with Asp8 and alendronate (a bisphosphonate) to deliver semaphorin 4d (*Sema4d*) siRNAs to specific bone sites, exhibiting partial counteraction of bone loss originating from osteoporosis ([@bib239], [@bib241]). Recently, this research team fabricated a PLLA scaffold incorporating siRNA-*Sema4d* to improve bone formation in osteoporosis-related bone defects ([@bib242]). *Sema4d*, also known as CD100, was proved to be expressed by osteoclasts and negatively regulated osteoblastogenesis ([@bib143]). It has been reported that the physical chemistry of bone-formation surfaces covered with osteoblasts is characterized by lowly crystallized hydroxyapatite, while the physical chemistry of bone-resorption surfaces covered with osteoclasts is characterized by highly crystallized hydroxyapatite ([@bib201]). As two bone-targeted molecules, (AspSerSer)~6~ and Asp~8~ both demonstrated effective bone targeting functions ([@bib237], [@bib200]). The stronger affinity of (AspSerSer)~6~ to lowly crystallized hydroxyapatite rather than highly crystallized hydroxyapatite provided an explanation for the preferential binding of (AspSerSer)~6~ to bone-formation surfaces, whereas the stronger affinity of Asp~8~ to highly crystallized hydroxyapatite rather than lowly crystallized hydroxyapatite produced a preferential binding of Asp~8~ to bone-resorption surfaces ([@bib237]). The different affinity of these two molecules to the bone-formation or resorption surfaces deserves great attention in the siRNA-based bone anabolic therapy.

Except for polymer-based particles, polymeric hydrogels with controllable three dimensional networks have also been used for siRNA delivery in bone regeneration. Nguyen and colleagues described a localized and sustained Noggin siRNA DDS, based on engineered poly(ethylene glycol) (PEG) hydrogels scaffolds, which exhibited a controlled releasing course of 3--6 weeks and well-guided osteogenic differentiation of hBMSCs ([@bib145]). Their work provided an efficient methodology for realizing controlled stem cell fate in bone tissue engineering in the future. Furthermore, Manaka and colleagues examined the efficacy of Noggin-siRNA delivered by a biodegradable hydrogel (poly-~D,L~-lactic acid-*p*-dioxanone-polyethylene glycol block co-polymer, PLA-DX-PEG), which displayed enhanced BMP-induced ectopic bone formation ([@bib127]). Noggin is a major extracellular antagonist of BMPs, and Noggin silencing by siRNA exhibited significantly accelerated osteoblastic differentiation *in vitro* and promoted new bone formation *in vivo* ([@bib197], [@bib188]). However, the effect of local inhibition of Noggin expression by targeting siRNA transfection *in vivo* was not as dramatic as expected from the *in vitro* findings, which may due to the inadequate dose of Noggin-targeted siRNA and/or insufficient efficacy of the delivery system for siRNA into cells. Even though plenty of siRNA-based targeting systems have been effectively confirmed *in vitro* as mentioned before, a number of *in vivo* investigations are badly required to further determine the application efficacy of those siRNA-based targeting therapeutic in bone disorders.

4.2. siRNA-mediated therapy for bone tumour {#sec4.2}
-------------------------------------------

In addition to the investigations of the potent application of siRNAs to combat bone defects and resorption, siRNAs could be also efficient and anticipated tools to restrain tumour development and metastasis to the skeletal system. As a sequence-specific gene -silencing tool at the post-transcriptional level, siRNAs have been widely explored for targeting specific oncogenes, leading to effectively impeded bone tumour growth and ameliorated chemosensitivity.

It is widely acknowledged that VEGF regulates tumour angiogenesis by directly increasing neovascularization, vascular permeability and remodelling ([@bib15]). Silencing of VEGF via siRNAs was confirmed to suppress osteosarcoma angiogenesis and to promote tumour cell apoptosis via activation of phosphoinositide 3-kinase (PI3K) and the protein kinase B (AKT) signalling pathway in SaOS-2 cells ([@bib152]). Moreover, combined application of VEGF-siRNA and neoadjuvant chemotherapy manifested preferable synergistic therapeutic effect to simple biological therapy or VEGF-siRNA plus anti-angiogenesis chemotherapy in OS-bearing rats, suggesting that the addition of neoadjuvant chemotherapy might be beneficial for enhancing the therapeutic efficiency of VEGF-siRNA ([@bib250]). Translationally controlled tumour proteins (TCTPs), such as Mcl-2 (known as a Bcl-2 family member), have been described as stabilizing and promoting the anti-apoptotic activity of several oncogenes, thus facilitating the progression of tumour cells ([@bib118]). siRNA-mediated silencing of TCTP displayed obviously promoted apoptosis of the Saos-2 and U2OS cell lines, together with inhibited development of xenografts in nude mice ([@bib172]). The L1 cell adhesion molecule (L1CAM), belonging to the immunoglobulin superfamily, has been identified as a critical mediator of tumour progression. Based on the discovery of high expression of L1CAM in androgen-insensitive and metastatic prostate cancer (PC) cell lines, Sung et al. investigated the therapeutic effects of liposome-encapsulated L1CAM-siRNAs exhibiting admirable suppression of PC proliferation and bone metastasis through the inhibition of matrix metalloproteinase-2 (MMP-2) and MMP-9 and activation of the NF-κB pathway ([@bib182]). However, the mechanism by which the L1CAM regulates mesenchymal-to-epithelial transition (EMT)-related gene expression and confers enhanced motility and metastatic capabilities to PC remains to be further determined.

Multidrug resistance (MDR) represents an enormous barrier in the treatment of osteosarcoma. The recovery rate is dramatically decreased in patients with recurrence caused by MDR ([@bib169]). Overexpression of membrane-bound drug transporter proteins, including MDR-related proteins (ABCC1, ABCC2, MRP1 and MRP2), P-glycoprotein (P-ag, ABCB1) and breast cancer resistance proteins (ABCG2 and BCRP), is one of the considered causes of MDR ([@bib120]). To overcome MDR in treating OS, Susa and colleagues fabricated MDR1-siRNA-loaded, lipid-modified, dextran-based polymeric nanoparticles, suggesting that this approach could reverse drug resistance of MDR cell lines via effective suppression of P-ag expression ([@bib183]). Similarly, siRNA-mediated down-regulation of P-ag also displayed restored chemosensitivity in chemoresistant carcinoma and sarcoma cell lines ([@bib153]). To improve further therapeutic efficiency against MDR, Chen and colleagues studied multifunctional nanoparticles with modified delivery properties ([@bib27]). In their work, liposome-polycation-DNA (LPD) was sequentially modified with cationic lipid, VEGF-siRNA and doxorubicin (Dox) to improve drug uptake and penetration and to suppress angiogenesis. For the sake of inhibition of the drug efflux mediated by P-glycoprotein, they finally designed an anionic LPD, which exhibited significantly improved entrapment efficiency of Dox over cationic LPD. This exploration was the first to co-deliver the chemotherapy agent and oncogene-targeting siRNAs to overcome MDR in different carriers, providing a novel insight into the designing of multi-functional gene-delivery systems to solve MDR in future clinical practice.

Furthermore, siRNA-based gene delivery systems have also been applied in other bone neoplasms. Cheng et al. observed that CD147 expression affected the recurrence rate of GCTB after a clinicopathological analysis of 80 cases and CD147 knockdown by siRNA revealed dramatically inhibited proliferation, migration and invasion of GCTB cells *in vitro* ([@bib29]). Lau and colleagues found that p63 was an important factor facilitating GCT tumourigenesis via suppression of p53 by binding to the CDC2 and CDC25C p53-REs, and knockdown of p63 by siRNA manifested greatly decreased proliferation and promoted the apopotsis of GCT stromal cells ([@bib98]). Bertrand and colleagues described that silencing of *EWS/FLI-1* (one of the critical oncogenes in Ewing sarcoma) by siRNAs delivered by hydrogenated cationic nanodiamonds (ND-H) had enhanced the cytotoxic impact of vincristine on Ewing sarcoma (ES) cells ([@bib12]). Nanodiamonds (NDs), which are suitable for surface modification with therapies, targeting, or labelling of moiety due to their carbon-related surface chemistry, were reported to deliver siRNAs to ES cells by targeting the oncogene *EWS/FLI-1* ([@bib4]). This siRNA delivery system not only exhibited strongly suppression oncogene expression, but also enhanced the cytotoxic effect of vincristine, a chemio-therapeutic agent already used in clinics to treat Ewing sarcoma. Therefore, ND-H constitutes a great promising platform for siRNA delivery in anti-bone cancer therapy.

Cancer-induced bone pain is a severe clinical issue affecting the quality of life of patients and even therapeutic outcomes. Recently, siRNA-based gene treatment emerged as an anticipated method to attenuate bone cancer pain (BCP). Huang and colleagues reported that silencing of phosphatidylinositol 3-kinase cb (*PI3Kcb*) alleviated BCP by increasing glial excitability ([@bib74]). Toll-like receptor 4 (TLR4) has been preliminarily corroborated to be an important synergistic factor involved in proinflammatory cytokine-mediated neuron-to-glial signal activation ([@bib97]), and siRNA-mediated down-regulation of TLR4 yielded obviously attenuated nociception in rats with BCP ([@bib151]). It was reported that hyper-active platelet-derived growth factor (PDGF) could induce tactile, allodynia and selective inhibition of PDGF receptor (PDGFR) produced suppressed tactile allodynia and thermal hyperalgesia ([@bib132]). Based on this discovery, Xu and colleagues observed that siRNA-mediated PDGF knockdown effectively relieved BCP by blocking the AKT/ERK signalling pathway ([@bib228]). Central sensitization promotes the development of BCP and cAMP response element binding protein (CREB), which is positively regulated by CREB-regulated transcription coactivator1 (*CRTC1*), which in turn plays a critical role in central sensitization ([@bib13]). Liang and colleagues observed that suppression of spinal *CRTC1* by siRNA resulted in effectively reduced BCP in mice orthotopically implanted with OS cells ([@bib111]). These studies discussed above may provide further insight into the mechanisms of cancer pain, and contribute to the development of therapeutic strategies for clinical treatment of bone cancer pain.

4.3. siRNA-mediated therapy for other non-lethal diseases {#sec4.3}
---------------------------------------------------------

Some other non-lethal diseases, such as osteoarthritis, osteonecrosis and heterotopic ossification, also exert many adverse effects on the quality of life of patients. Recently, siRNA-based targeting gene technologies have offered potential benefits for the treatment of these bone-related diseases. Corticosteroids have been widely used in some infectious and rheumatoid diseases such as severe acute respiratory syndrome (SARS) and rheumatoid arthritis. However, steroid-associated osteonecrosis (SAON) usually occurs after pulsed steroid application for these diseases ([@bib225]). Destructive bone repair is one of the most important pathological changes involved in SAON, which is characterized by obvious bone resorption and vascular hyperpermeability. VEGF mainly contributes to vascular hyperpermeability and it potentially mediates osteoclastic bone resorption ([@bib90]). Src, which is a downstream molecule of VEGF signalling encoded by the *c-src* gene, participates in osteoclastic bone resorption and VEGF-induced vascular permeability ([@bib14]). Zheng and colleagues performed systematical evaluation of the therapeutic efficiency of Src blockage by siRNA with regard to SAON both *in vitro* and *in vivo*, and they revealed that siRNA-mediated Src suppression significantly suppressed VEGF-induced osteoclastic bone resorption and vascular hyperpermeability by destroying osteoclast cytoskeletons and maintaining endothelial junctional integrity ([@bib246], [@bib247], [@bib19]). Moreover, they determined that up-regulation of VEGF expression in chondrocytes derived from femoral head osteonecrosis in pigs was mediated partially by HIF-1α, and silencing of HIF-1α by siRNA transfection led to obviously decreased VEGF expression ([@bib238]). Therefore, suppression of VEGF expression using siRNA technology might gain desirable therapeutic value in preventing destructive bone repair due to SAON. Li and colleagues further reported that blockage of peroxisome proliferator-activated receptor-γ (*PPAR-γ*) by siRNA inhibited adipogenesis and enhanced osteogenesis in BMSCs, thus providing a novel avenue for impeding the development of SAON ([@bib105]). *PPAR-γ* is a specific transcriptional factor correlated with adipogenesis, and knockout of *PPAR-γ* in BMSCs led to increased osteoblastogenesis ([@bib20]). This evidence indicates that PPAR-γ is an significant target gene in the development of SAON.

Analogous to the miRNA-mediated targeting therapy for OA, siRNA-based gene-specific therapeutics have displayed potential treatment value in degenerative diseases as well. MMP-13 was reported to facilitate the progression of OA due to its preferential digestion of type II collagen in the early stage of cartilage degradation ([@bib187]). Akagi and colleagues demonstrated that intra-articular injection of MMP-13 siRNA in the early stage of a surgically-induced murine OA model showed delayed cartilage degradation ([@bib2]). However, it remains to be determined whether the duration of MMP-13 siRNA retention is altered in joints with experimental OA, and the knockdown effect mediated by siRNA in other tissues such as cartilage should also be investigated. Autologous chondrocyte implantation (ACI) is a cell-based therapy and was first reported in 1994 ([@bib16]). Since then, it has been widely performed on more than 12,000 patients with OA. However, the success of ACI always depends on the phenotypic stabilization of chondrocytes. Legendre et al. observed that the gene blockage of collagen type I alpha 1 (*COL1A1*) and high temperature requirement factor A1 (*HtrA1*) via siRNA induced an distinctly enhanced differentiation index of chondrocytes cultured with BMP-2 under hypoxic conditions, thus offering the potential opportunity to explore novel ACI-based treatment in the future ([@bib101], [@bib148]). It was corroborated that overexpression of ADAMTS-5 mediated by IL-1β induced aggravated degradation of cartilage matrix in OA and significantly inhibited miR-30a expression levels ([@bib81]). siRNA-mediated blockage of ADAMTS-5 demonstrated protective effects on cartilage degradation ([@bib32]). Moreover, intra-articular delivery of hypoxia-inducible factor-2α (HIF-2α) siRNA by chondrocyte-homing nanoparticles resulted in considerably decreased expression of some catabolic proteins involved in the progression of OA, such as MMP-13, VEGF, and ADAMTS-5, thus providing better prevention of cartilage degeneration in OA patients ([@bib154]). The hypoxia signalling pathway involved in bone and cartilage regeneration was comprehensively summarized in a detailed review ([@bib180]), and further research is badly needed to determine hypoxia-associated gene targeting strategies to improve the therapeutic potential regarding to OA.

Additionally, siRNAs have also been used to explore potential therapies for autosomal dominant diseases in bone, which are characterized by severe morbidity and lack of effective treatments. It has been verified that Albers-Schönberg disease, also called autosomal dominant osteopetrosis type 2 (ADO2), is characterized by significantly inhibited osteoclast activity, mainly due to heterozygous missense mutations of the *CLCN7* gene. Capulli et al. reported a *CLCN7-*specific siRNA-based exploration using a cationic polymer transfection reagent both *in vitro* and *in vivo*, leading to overall improvement in the osteopetrotic bone phenotype ([@bib22]). This study provided a feasible siRNA-based therapeutic strategy for *CLCN7-*dependent ADO2, and it emphasizes the translational impact of future treatment on the therapeutically neglected osteopetrosis.

5. Summary of delivery systems and clinical status in small non-coding RNAs-based therapeutics for bone-related disorders {#sec5}
=========================================================================================================================

The primary role of a delivery system is to facilitate the cellular uptake of miRNAs or siRNAs to their target sites. A delivery system can also protect nucleic acids from premature nuclease degradation, which can affect the specificity and functionality of the RNA molecules. It has been well documented that miRNAs or siRNAs themselves are prone to nuclease degradation with low cell membrane penetration capability due to their highly charged backbones. In addition, inflammation-related cell toxicity and unintended gene knockdown caused by off-target effects derived from the application of miRNAs or siRNAs should be paid great attention when delivering them *in vivo*. Thus, establishing rational and effective miRNAs- or siRNAs-based drug delivery systems (DDSs) is of great importance to their targeting therapeutics in bone disorders. Since miRNAs and siRNAs have similar physicochemical properties (double-stranded RNAs with 20--25 nucleotides) and the same intracellular sites of actions (both require enzymatic functions of the RISC to be active against target mRNAs), similar delivery technologies can be applied to both types of RNA molecules.

There are mainly two types of DDSs for transferring miRNAs or siRNAs: viral-mediated and non-viral vectors. Viruses, such as lentiviruses, retroviruses, adenoviruses, and herpesviruses, appear to be the first choices for miRNA or siRNA delivery, and they are extremely efficient in transferring RNA-encoding vectors into the nuclei of mammalian cells to ensure high expression of RNA. Almost 70% of gene therapy clinical trials have involved the application of viral vectors to deliver nucleic acids due to their high transduction efficiency ([@bib232]). In addition, long-term expression can be achieved using viruses. However, the major limitations of viral vectors are biological safety issues, including possible carcinogenicity, high viral toxicity and verified immunogenicity ([@bib202]). Therefore, despite the inferior transfection efficiency of viral vectors, non-viral transfer systems with low acute toxicity, lower production cost, non-infection and non-immunogenicity are emerging as a desirable approach to deliver miRNAs or siRNAs *in vivo* ([@bib26]). Two major categories of non-viral DDSs used for miRNAs or siRNAs delivery in therapeutic applications are lipid-based and polymer-based systems. Apart from the advantages mentioned above (i.e., relatively favourable safety profiles and low production costs), nonviral vectors are highly versatile. They can be easily modified to promote their delivery efficiency, for example, to improve serum stability and to extend the circulation time by PEGylation ([@bib17]), or to achieve site-specific delivery by incorporating targeting ligands (i.e., (AspSerSer)~6~ and Asp~8~) ([@bib237], [@bib110]). Despite efforts to develop suitable miRNA or siRNA delivery systems for clinical application, a poor correlation between *in vitro* and *in vivo* efficacies has also been observed, and it has often been reported that a delivery system functioned effectively *in vitro* but failed *in vivo* because of poor pharmacokinetic profiles, toxicity issues, immune responses or nonspecific uptake ([@bib122]). Therefore, the success of therapeutic miRNAs and siRNAs is highly dependent on the availability of an efficient and safe delivery system. Selected examples of viral and non-viral delivery systems that have been explored to deliver therapeutic miRNAs and siRNAs both *in vivo* and *in vitro* are summarized in [Table 1](#tbl1){ref-type="table"} and [Table 2](#tbl2){ref-type="table"} , respectively. For a better understanding of the nucleic acids and gene delivery, please refer to the chapter summarized by [@bib3] Table 1Summary of preclinical investigations on miRNAs-mediated targeting therapeutics in bone-related disorders.Table 1DisordersmiRNADelivery systemRegulationGene of interest*In vitro*/*In vivo*Outcome summaryReferenceOsteoporosis (OP)mmu-miR-17/20a-5pLipofectamine 2000 complexes↑*RANKL*MC3T3-E1, C57BL/6 mice窗体顶端([@bib175])Attenuated Dexamethasone- induced osteoclast differentiation and functionmmu-miR-29a-3pLentivirus↑*Dkk-1*SD ratProtects against GC-induced bone loss and fragility([@bib207])mmu-miR-34a-5pX-tremeGENE Transfection Reagent↓*CDK4, CDK6,*C57BL/6 mice窗体顶端([@bib85])*Cyclin D1*Impaired BMSC osteogenic differentiation and aggravated osteoporsismmu-miR-140/214-3pBaculovirus vectors↓*JAG1, Tmem119, ATF-4, Osterix*SD ratPromoted bone formation and mitigated excessive bone resorption([@bib109])mmu-miR-34a-5pLipofectamine\
RNAi MAX↑*Tgif2*C57BL/6J miceElevated bone resorption and reduced bone mass([@bib95])Bone defecthsa-miR-21-5pChitosan/hyaluronic acid nanoparticles↑*Runx2*hBMSCSignificantly improved osteogenesis([@bib168], [@bib209])mmu-miR-26a-5pLipofectamine 2000 complexes↑*OCN, COL1*窗体顶端Satisfactory bone repair in tibial defect([@bib208])Rabbit ASCmmu-miR-29a-3pGelatin solutions↓*IGF1, tfgb1*MC3T3-E1Significantly enhanced ECM deposition([@bib80])mmu-miR-31-5pLipofectamine 2000 complexes↓*Runx2, Satb2*SD ratGood biocompatibility and bone regeneration([@bib40], [@bib39])mmu-miR-138-5pLipofectamine 2000 complexes↓*Runx2*C57BL/6 mice,窗体顶端([@bib229])rat BMSCMassive bone with good vascularizationhsa-miR-148b-3pSilver nanoparticle complexes↑*Runx2, OCN*hASCPromoted osteogenic differentiation([@bib156])Primary bone tumorhsa-miR-20a-5pLipofectamine 2000 complexes↓*EGR*MG63, SaSO2, SW1353Inhibited cell proliferation and cycle([@bib249])hsa-miR-22-3pLipofectamine 2000 complexes↑*ACLY*SaSO2, PC3, Hela, A549Inhibited growth and metastasis of various tumors([@bib226])hsa-miR-26a-5pLentivirus vector↑*Jagged1*MG63, SaSO2, 143B, U2OS, BALA/c nude miceSuppressed CSCs phenotype and tumor growth([@bib121])hsa-miR-106a-5pLipofectamine 2000 complexes↑*HMGA2*MG63, SaSO2, HOS, U2OSInhibited proliferation, migration and invasion([@bib66])hsa-miR-106b-5pFuGENE HD transfection agent↑*RANKL, IL-8, MMP2, TWIST*mice BMM, GCTSC, OVX mouseInhibited bone resorption and osteolysis([@bib210])hsa-miR-126-5pFuGENE HD transfection agent↑*MMP-13, PTHrP*mice BMM, GCTSCSuppression of osteoclast differentiation and bone resorption([@bib220], [@bib248])hsa-miR-126-5pLipofectamine 2000 complexes↑*Sirt 1*SaSO2窗体顶端([@bib176], [@bib227])inhibited proliferation, migration, invasion and epithelial-mesenchymal transitionhsa-miR-204-5phsa-miR-145-5pLipofectamine 3000 complexes↓*FLI-1*MG63, SaSO2Inhibited tumor progression([@bib223])hsa-miR-409-3pLipofectamine 2000 complexes↑*Catenin-δ1*U2OSInhibited migration and invasion([@bib222])hsa-miR-646Lipofectamine 2000 complexes↑*FGF-2*MG63, SaSO2, HOS, U2OSSuppression of metastasis([@bib181])Secondary metastasishsa-miR-34a-5pLentivirus vector↑*TCF-7*PC3, RasB1Inhibited bone metastasis of Ras-activated PC([@bib28])hsa-miR-335-5p,Lentivirus vector↑*eNOS*PC3Inhibited bone metastasis of PC([@bib51])hsa-miR-543Osteoarthritis (OA)hsa-miR-23a-3p,Lipofectamine 2000 complexes↓*Samd3*SW1353Promoted type II collagen and aggrecan expression([@bib86], [@bib106])hsa-miR-16-5phsa-miR-139-5pLipofectamine\
RNAi MAX↓*EIF4G2, IGF1R*CHON-001Protective effects on chondrocyte proliferation and migration([@bib73])hsa-miR-142-3pLipofectamine 2000 complexes↑*HMGB-1*C57BL/6 miceSuppressed inflammation and chondrocyte apoptosis([@bib212])mmu-miR-210-5pGeneporter 2\
Transfection Reagent↑*DR6*SD ratSuppressed inflammation and chondrocyte apoptosis([@bib240])hsa-miR-365a-3pLipofectamine 2000 complexes↓*HDAC4*Primary chondrocyte from OA patientInhibited expression of MMP13 and Col X([@bib231])Table 2Summary of preclinical investigations on siRNAs-mediated targeting therapeutics in bone-related disorders.Table 2DisordersTargeting geneDelivery system*In vitro*/*In vivo*Outcome summaryReferenceBone formation and resorption*FPPS*DharmaFECT4 (cationic lipid transfection reagent)rat BMSC, MC3T3-E1Selectively inhibiting osteoclast-mediated bone resorption and improving osteoblast differentiation without effects on osteoblast mineralization([@bib203])*GNAS1, PHD2*Ambion (polyamine-based transfection agent)hBMSC, Sheep (local administration)Both support bone regeneration *in vivo*, whereas only siGNAS1 promoted collagen I and osteopontin expression *in vitro*([@bib163])*siFlt-1, Ckip-1*Lipofectamine 2000 complexesrat BMSC, SD rat (local administration)Satisfactory angiogenesis and osteogenesis in BMSCs and bone repair efficacy *in vivo*([@bib83])*Ckip-1*Lipofectamine 2000 complexesMC3T3-E1,, C57/BL mice, SD rat (tail vein injection)Increased osteogenic differentiation *in vitro* and reversed bone loss in osteoporotic mice([@bib59])*Plekho1*DOTAP cationic liposomesSD rat (tail vein injection)Increased bone microarchitecture and bone formation in both healthy and osteoporotic rats.([@bib237])*Plekho1*LNPsSD rat (tail vein injection)Improved bone mass in osteoporotic rats([@bib110])*RANK*Cationic liposome DMAPAP/DOPEC57BL/6 mice (local administration)Effectively impeded osteolysis and increased bone formation([@bib34])*RANK*PLGA microparticlesmice BMSCInhibited osteoclastic phenotype([@bib205])*GCR*PLGA microparticleshBMSCImproved osteogenic proliferation and differentiation([@bib69])*Sema4d*HPMA copolymerBalb/c; Kunming mice (intravenous injection)Partly counteracted bone loss originated from osteoporosis([@bib239], [@bib241])Bone formation and resorption*Sema4d*PLLA scaffoldWistar rat (local administration)Improved bone formation in osteoporosis-related bone defects([@bib242])*Noggin*PEG hydrogels scaffoldshBMSCWell guided osteogenic differentiation([@bib145])*Noggin*PLA-DX-PEGICR mice (local administration)Enhanced BMP-induced ectopic bone formation([@bib127])Bone tumor*VEGF*Adenoviral vectorSaSO2Suppressed osteosarcoma angiogenesis and promoted apoptosis([@bib152])*VEGF*Adenoviral vectorSD rat (intratumoral injection)Inhibited tumor growth([@bib250])*TCTP*Lentiviral particlesSaSO2, U2OS, MG63,nude mice (subcutaneous injection)Promoted cell apoptosis and inhibited development of xenografts([@bib172])*L1CAM*Liposome SNPC3, nude mice (intratumoral injection)Admirable suppression of PC proliferation and bone metastasis([@bib182])*ABCB1*Lipid-modified dextran polymerKHOS~R2~, U2OS~R2~Reversed drug resistance of MDR cell lines([@bib183])*ABCB1*LipofectanthMNNG/HOS, 293TRestored chemosensitivity in MDR cell lines([@bib153])*VEGF*liposome-polycation-DNA (LPD)NCI/ADR-RES,OVCAR-8, nude mice (tail vein injection)Reversed MDR by multi-functional gene delivery systems([@bib27])*CD147*Adenoviral vectorPrimary GCTB from patientDramatically inhibited proliferation, migration and invasion of GCTB cell([@bib29])*P63*Lipofectamine RNAiMAXPrimary GCTSCs from patientDramatically inhibited proliferation of GCTB cell([@bib98])Bone tumor*EWS/FLI-1*hydrogenated cationic nanodiamondsA673 human; Ewing sarcoma cell lineStrongly inhibited oncogene expression and enhanced cytotoxic effect of vincristine([@bib12])*PI3Kcb*Adenoviral vectorMADB-106, SD rat (local administration)Alleviated bone cancer pain (BCP) by increasing glia excitability([@bib74])*TLR4*Adenoviral vectorWalker256, SD rat (intrathecal injection)Attenuated nociception in rats with BCP([@bib151])*PDGFR*HSV vectorSD rat (subarachnoid administration)Effectively relieved BCPin the spinal cord([@bib228])*CRTC1*Adenoviral vectorNCTC2472, C3H/HeNCrl/Vr mice (intrathecal injection)Reduced BCP in mice orthotopically implanted with OS cells([@bib111])SAON*Src*Lipofectamine 2000 complexesNew-Zealand white Rabbit (local administration)Inhibited destructive repair of osteonecrosis([@bib246], [@bib19], [@bib247])*PPAR-γ*Adenovirus shuttle vectorNew-Zealand white Rabbit (local administration)Inhibited adipogenesis of BMSCs and prevention of SAON in rabbit([@bib105])*MMP-13*Dharmacon AccellC57BL/6 mice (intra-articular injection)Delayed cartilage degradation at the early stage of OA development([@bib2])*COL1A1, HtrA1*Type I collagen spongesHuman articular chondrocyte (HAC), rabbit articular chondrocyte (RAC)Enhanced differentiation index of chondrocytes cultured with BMP-2 under hypoxia condition([@bib101], [@bib148])*ADAMTS-5*Lentivirus vectorSD rat (intra-articular injection)Protective effect on cartilage degradation([@bib32])*HIF-2α*Chondrocyte- homing nanoparticlesMouse (intra-articular injection)Inhibited catabolic proteins expression in OA, and maintained cartilage integrity([@bib154])ADO2*CLCN7*LipofectamineRAW264.7, Human osteoclasts, mice (subcutaneous injection)Inhibited increase of bone mass in growing ADO2 mice([@bib22])

The first clinical trial of a miRNA therapy began in 2013, with the second one starting in early 2015. In contrast, the first clinical trial of a siRNA therapeutic was initiated in 2004 ([@bib149]). Through searching on **ClinicalTrials.gov**, to date, we found approximately 50 siRNA candidates that have reached various stages of clinical trials for the treatment of different diseases, and approximately 50% of these trials are focused on tumour-related targeting therapeutics. However, the clinical development of miRNAs as therapeutics is lagging significantly, with only the two miRNA therapeutics mentioned above, both of which are indicated for the treatment of cancers. The relatively slow progress of miRNA therapeutics is mainly due to their uncertain mechanisms and complex roles of action and specificity during the early years of their discovery. In addition, the diverse potential applications (e.g., as drug targets and biomarkers) of miRNAs, which have been extensively discussed before, might also have detracted from their development as therapeutic agents. However, all of the therapeutic miRNAs or siRNAs in clinical trials are either for topical administration (i.e., ocular or dermal), or they systemically targeting the liver, where most injected RNAs end up non-specifically anyway. Unfortunately, there have been no clinical trials initiated for bone-related disorders at the time of our writing. Therefore, many efforts still must be exerted for the improvement and better understanding of miRNA and siRNA therapeutics, which will be discussed latter.

6. Challenges facing small non-coding RNAs-based therapeutics in bone-related disorders {#sec6}
=======================================================================================

Synthetic miRNAs and siRNAs hold great promise as new classes of therapeutic agents by silencing genes of interest, and they have been studied for the treatment of various human diseases, such as cancers, genetic disorders, cardiovascular diseases and bone-related disorders. It has been well documented that miRNAs and siRNAs have similar physicochemical properties that are involved in the regulation of gene silencing, yet their mechanisms of action are different; thus, the requirements for sequence design and therapeutic application are distinct. The major difference between them is that the former has multiple mRNA targets, whereas the latter is highly specific, with only one target. Therefore, in some complex multi-genic diseases, miRNAs might have predominance over siRNAs. The design of miRNAs is more straightforward than that of siRNA when used for bone therapeutics because the sequence of the former should be almost, if not entirely, identical to the endogenous miRNA of interest. Moreover, miRNAs have an advantage over siRNAs as therapeutics for complex multigenic bone-related diseases, such as congenital dislocation of the hip (CDH) and rachischisis, which require modulation of multiple pathways for effective treatment. With the ability to inhibit the expression of a number of target genes, which often work together as a network within the same cellular pathway, a whole disease phenotype can potentially be altered through a single miRNA sequence. In contrast, the therapeutic potential of siRNAs is sometimes limited by their ability to target only one specific gene. Therefore, it could be challenging to employ siRNAs to regulate complex bone-related diseases.

Based on the overall analysis of miRNA- and siRNA-based therapeutics mentioned above, we can know that these therapies have emerged as excellent genetic tools in bone biology, holding great therapeutic promise in the field of gene therapy. However, there are several universal challenges facing the application of miRNA and siRNA therapeutics, although one of the distinctive features that differentiate siRNAs from miRNAs is that siRNAs are designed to silence the expression of a specific target mRNA, leading to the downregulation of unintended, unpredicted targets, which are also called off-target effects. Three main off-target effects of siRNAs were discovered with potentially unwanted side effects almost a decade ago ([@bib79]). Firstly, silencing of many unintended genes through partial sequence complementarity always produces adverse effects on the normal biology. In addition, there was an inflammatory response caused by either the siRNA itself or the DDS used. Finally, the saturation of endogenous RNAi machinery could inevitably affect normal miRNA functionality. Thus, one of the major challenges of siRNA therapy is to reduce off-target effects, which have been verified to compromise the therapeutic effects and specificity and can even lead to cell death ([@bib46]). It is also important to have a clear overview of the barriers to *in vivo* treatment with miRNAs and siRNAs. Obstacles to miRNA or siRNA delivery depend on the target organ and route of administration. Different *in vivo* administration routes will encounter different physiological barriers. For instance, intravenous administration is the most commonly used technique, and the endothelial wall in the vasculature serves as the primary barrier to RNA delivery. Moreover, the mononuclear phagocytes and reticulo-endothelial system are responsible for the physiological barriers that hinder miRNAs or siRNAs from reaching their targets, leading to reduced therapeutic efficacy. Furthermore, both miRNA and siRNA therapeutics face the same major challenges of prolonged and stable delivery, improved potency and minimized cell and tissue toxicity. Finally, several current *in vitro* studies with therapeutic RNAi have provided results that are largely not comparable with *in vivo* results with the same reagents. This disconnect is a current barrier to predictability and reliability for clinical translation.

7. Conclusion and future expectation {#sec7}
====================================

miRNAs and siRNAs, both of which exert gene silencing effects on physiological and pathological processes at the post-transcriptional level by targeting relevant and specific mRNA, represent innovative and promising breakthroughs in the field of genetic engineering. Remarkable progress has been made in the biological, diagnostic and therapeutic potential of these two small non-coding RNAs for bone metabolism and bone-related disorders. The experience from antisense and gene therapy has contributed to the rapid progress of miRNAs and siRNAs in clinical studies and in particular, the technology of the chemical modification and delivery of nucleic acids developed previously can be applied to both miRNAs and siRNAs. Thorough investigation and full understanding of the function of miRNAs involved in various bone-related physiological and pathological activities hold great significance for the design of specific and accurate gene-silencing therapeutics mediated via siRNAs.

Currently, siRNAs have demonstrated obvious superiority over miRNAs in the progress of advancing into clinical trials, as discussed before. Orthopaedic applications for therapeutics RNAs have the advantage of the surgeon entering the site of therapy surgically for repair, allowing RNA to be administered locally to these sites (topically or in combination with a device). The most attractive aspects of miRNA and siRNA therapeutics are their abilities to target virtually any genes, which might not be possible with protein-based drugs or small molecules. While the therapeutic efficacy of miRNAs and siRNAs has been successfully shown both *in vitro* and *in vivo*, several technical barriers still must be overcome for these RNA molecules to be used clinically. While the majority of the literature focuses on miRNA or siRNA expression and gene targeting, there is a need to assess their processing and architecture because they are closely related to the targeting effects of MSC differentiation. There remains a need for more studies evaluating the regulation of miRNA or siRNA processing and biogenesis during osteogenesis and their related proteins, which could lead to novel mechanisms for miRNA- or siRNA-based interventions in bone disorders. To avoid silencing of unintended genes, lowering the concentration of miRNAs or siRNAs used could be an effective approach for reducing these unwanted side-effects mentioned above, while decreasing the concentration to the minimally effective limit can also significantly alleviate the burden on RNAi machinery and avoid disrupting physiological processes. For proper therapeutic use, the sequences of RNA must be carefully designed to avoid any specific or nonspecific unwanted side effects and immune responses. To avoid the off-target effects induced by siRNAs, one feasible approach is to reduce the complementarity between the seed region (2--7 nucleotides of 5′ end) of the siRNA and the 3′UTR of the mRNA. In addition, the siRNA should have a low thermodynamic stability of the duplex between the seed region of the guide strand of the siRNA and its target mRNA since a low seed-target duplex stability reduces the ability of the siRNA to trigger seed-dependent, off-target effects ([@bib141]).

The use of nonviral vectors, including polymer-based or lipid-based delivery systems, offers the advantages of better safety profiles and lower production costs compared to viral vectors, despite inferior delivery efficiency. In addition, there are also a few additional design criteria that can promote the efficacy of miRNA and siRNA therapeutics in bone. Incorporation of miRNA-or siRNA-loaded particles inside injectable biodegradable matrices might be highly favorable in localizing the delivery of miRNAs or siRNAs to the sites of bone defects, osteoporosis or tumour, thus, maximizing the therapeutic effect. Meanwhile, such an approach would also circumvent many physiological barriers in the case of systemic administration. The addition of targeting moieties is considered to be another significant approach to improving the efficacy of siRNA delivery. The three most commonly used moieties for bone-related disorders are bisphosphonates, bone-specific oligopeptides and aptamers, which have been discussed before ([@bib237], [@bib110], [@bib200], [@bib239], [@bib241]). The discovery of molecules with high affinity for bone surfaces will improve the therapeutic effect and clinical relevance of miRNA- or siRNA-based delivery systems. In addition to improving the therapeutic effects of any miRNA or siRNA therapies analysed above, there are also safety issues to be considered to move the technology into a clinical setting. It is very important to fabricate the DDS and injectable matrices with biocompatible and degradable biomaterials, with degradation byproducts that are noncytotoxic, and with materials can be cleared rapidly and readily from the body without accumulation in the liver or other organs. Cationic polymers have been extensively used for oligonucleotide delivery due to their capability to complex readily with RNA or DNA as mentioned above ([@bib203], [@bib237], [@bib34]). However, upon degradation some cationic polymers can induce cytotoxic effects on surrounding cells and can cause red blood cell lysis ([@bib48]). Therefore, hydrolysable polymers, such as cyclodextrin-containing polymers, which can degrade more readily and rapidly, could gain greater attention when designing the DDS involved in miRNA-or siRNA-based therapeutics. In addition, the duration of silencing effect after a single dose of miRNAs or siRNAs depends on several factors, such as the stability of the RNA molecules, the rate of RNA release from the delivery system, the type of target tissues, together with the half-life and turnover rate of the target proteins. A good understanding of this area could also contribute to the rational design of therapeutic strategies to promote clinical outcomes of miRNA and siRNA treatments. For instance, PEGylated nanoparticles incorporating targeting ligands might be effective for avoiding reticulo-endothelial system (RES) clearance, thus prolonging the circulation time and the stability of miRNA and siRNA delivery systems.

To improve the stability of miRNAs and siRNAs as therapeutic agents, relevant chemical modifications of RNA were developed initially to address this issue. Successful chemical modification should not compromise the gene-silencing efficiency of these RNA molecules. The major types of chemical modification that are commonly investigated in miRNA and siRNA design including locked and unlocked nucleic acids, ribose 2′-OH groups and phosphorothioate modifications ([@bib5]). Different RNA modifications can be used to serve various functions, and proper chemical modification is also an effective approach for reducing the off-target effects analysed above. Efficient gene silencing can also be achieved with naked RNA; however, this approach might be limited to local administration to organs such as the lungs and the eyes. Additionally, proper chemical modification (such as incorporation of specific nuclease inhibitors) of the RNA molecule could be beneficial for improving its stability against nuclease activity in the airway fluid of the lungs or in the vitreous humour of the eye. Although miRNA-and siRNA-based therapy remains a nascent field in bones, it is expected that with advances in RNA design, specific biochemical modifications and better understand-ing of the effects and duration of gene silencing, miRNAs and siRNAs will realize a gradual and progressive translation of preclinical experiments into clinical trials in the near future.
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